MARVEL BIOSCIENCES CORP (MRVL.CA) Fundamental Analysis & Valuation

TSX-V:MRVL • CA57384M1077

Current stock price

0.175 CAD
-0.01 (-2.78%)
Last:

This MRVL.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MRVL.CA Profitability Analysis

1.1 Basic Checks

  • In the past year MRVL has reported negative net income.
  • In the past year MRVL has reported a negative cash flow from operations.
  • In the past 5 years MRVL always reported negative net income.
  • In the past 5 years MRVL always reported negative operating cash flow.
MRVL.CA Yearly Net Income VS EBIT VS OCF VS FCFMRVL.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -1M -2M -3M

1.2 Ratios

Industry RankSector Rank
ROA -333.11%
ROE N/A
ROIC N/A
ROA(3y)-451.19%
ROA(5y)-351.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRVL.CA Yearly ROA, ROE, ROICMRVL.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

1.3 Margins

  • MRVL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRVL.CA Yearly Profit, Operating, Gross MarginsMRVL.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. MRVL.CA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for MRVL has been increased compared to 1 year ago.
  • MRVL has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MRVL is higher compared to a year ago.
MRVL.CA Yearly Shares OutstandingMRVL.CA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
MRVL.CA Yearly Total Debt VS Total AssetsMRVL.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M

2.2 Solvency

  • Based on the Altman-Z score of -38.76, we must say that MRVL is in the distress zone and has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -38.76
ROIC/WACCN/A
WACCN/A
MRVL.CA Yearly LT Debt VS Equity VS FCFMRVL.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 2M -2M -4M

2.3 Liquidity

  • A Current Ratio of 0.16 indicates that MRVL may have some problems paying its short term obligations.
  • MRVL has a Quick Ratio of 0.16. This is a bad value and indicates that MRVL is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.16
Quick Ratio 0.16
MRVL.CA Yearly Current Assets VS Current LiabilitesMRVL.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MRVL.CA Growth Analysis

3.1 Past

  • MRVL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.81%.
EPS 1Y (TTM)-30.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. MRVL.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MRVL. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRVL.CA Price Earnings VS Forward Price EarningsMRVL.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRVL.CA Per share dataMRVL.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.01 -0.02 -0.03 -0.04 -0.05

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRVL.CA Dividend Analysis

5.1 Amount

  • No dividends for MRVL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MRVL.CA Fundamentals: All Metrics, Ratios and Statistics

MARVEL BIOSCIENCES CORP

TSX-V:MRVL (4/6/2026, 7:00:00 PM)

0.175

-0.01 (-2.78%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)06-17
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners23.39%
Ins Owner ChangeN/A
Market Cap11.03M
Revenue(TTM)N/A
Net Income(TTM)-2.28M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.06
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -333.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-451.19%
ROA(5y)-351.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.16
Quick Ratio 0.16
Altman-Z -38.76
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-48.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.52%
OCF growth 3YN/A
OCF growth 5YN/A

MARVEL BIOSCIENCES CORP / MRVL.CA Fundamental Analysis FAQ

What is the fundamental rating for MRVL stock?

ChartMill assigns a fundamental rating of 0 / 10 to MRVL.CA.


What is the valuation status for MRVL stock?

ChartMill assigns a valuation rating of 0 / 10 to MARVEL BIOSCIENCES CORP (MRVL.CA). This can be considered as Overvalued.


How profitable is MARVEL BIOSCIENCES CORP (MRVL.CA) stock?

MARVEL BIOSCIENCES CORP (MRVL.CA) has a profitability rating of 0 / 10.


Can you provide the financial health for MRVL stock?

The financial health rating of MARVEL BIOSCIENCES CORP (MRVL.CA) is 0 / 10.